Scientific Presentations
ForeseeHome
ARVO 2013 ANnual Meeting
| April 2013
ForeseeHome in AREDS2-Home Monitoring of AMD patients: Study Design, Enrollment, Baseline Characteristics and Initial Device Usage
Ramiro S Maldonado; Elvira Agron; Traci E Clemons; Emily Y. ChewThe successful enrollment, randomization and stable rates of initial FH compliance are encouraging. The study will help clarify the optimal strategies for monitoring patients with intermediate AMD for early detection of CNV.
FDA Intended Use
ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.
Media enquiries? Reach out to our Media Contact
